FDA Brief

Warning letters Drugs

FDA warning letter to

TKTX Numbing Cream USA

High riskIssued Feb 25, 2025Posted Mar 4, 2025Center for Drug Evaluation and Research (CDER)

FDA warned TKTX Numbing Cream USA that its lidocaine numbing creams are unapproved and misbranded new drugs.

What happened

FDA reviewed the company's website, where the creams are sold in the U.S. without a prescription, rather than conducting an inspection. FDA found the labels state 5% lidocaine, above the 0.5% to 4% range allowed for over-the-counter external pain relievers, and that the Gold and Black versions also contain prilocaine, which is not allowed in any such over-the-counter standard. The labels also promote use before tattooing, piercing and laser procedures, which are not permitted uses for these over-the-counter products.

What FDA found

  1. The creams are new drugs sold without an FDA-approved application, which federal law requires.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. The labels state 5% lidocaine, above the 0.5% to 4% range allowed for over-the-counter external pain relievers.

    Section 505G, 21 U.S.C. 355h; OTC Monograph M017
  3. The Gold and Black creams contain prilocaine, an ingredient not allowed in this or any over-the-counter drug standard.

    Section 505G, 21 U.S.C. 355h; OTC Monograph M017
  4. The labels claim use for tattooing, piercing and laser procedures, which are not allowed uses for an over-the-counter external pain reliever.

    Section 505G, 21 U.S.C. 355h; OTC Monograph M017
  5. The products are misbranded because they are nonprescription drugs that do not meet the requirements for marketing without an approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)
  6. FDA said these high-strength numbing creams may be applied over large or broken skin and covered with plastic wrap before cosmetic procedures, which can raise absorption and cause serious injury.

What FDA wants

FDA asks the company to write within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents, or to explain why it believes the products are legal. If more time is needed, the company must say why and give a completion date.

Who should pay attention

  • tattoo studios and artists who apply numbing creams
  • cosmetic and microblading clinics that use or recommend these products
  • online retailers and distributors selling imported numbing creams

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk